Xeris Biopharma Holdings (XERS) Revenue (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Revenue came in at $83.1 million in Q1 2026, up 38.27% YoY from $60.1 million in Q1 2025, and down 3.12% on a QoQ basis from $85.8 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Revenue (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Revenue data on file, last reported at $83.1 million in Q1 2026.
- Quarterly Revenue rose 38.27% year-over-year to $83.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.9 million (up 41.47% YoY) and the FY2025 annual result came in at $291.8 million, up 43.72% from the prior year.
- Revenue declined to $83.1 million in Q1 2026, from $85.8 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $85.8 million in Q4 2025 to a low of $22.1 million in Q1 2022.
- A 5-year average of $50.1 million and a median of $48.1 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue jumped 184.15% — and 2024, when it grew 12.31%.
- Tracing XERS's Revenue over 5 years: stood at $33.1 million in 2022, then soared by 33.93% to $44.4 million in 2023, then jumped by 35.39% to $60.1 million in 2024, then surged by 42.78% to $85.8 million in 2025, then retreated by 3.12% to $83.1 million in 2026.
- The last three Revenue figures came in at $83.1 million (Q1 2026), $85.8 million (Q4 2025), and $74.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 4.14 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 2.47 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 7.65 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 783.30 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 3.76 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 959.00 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 1.37 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.54 Bn | 1.42 Bn | 79.59 Mn | 92.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.10 Mn |
| Mar 31, 2026 | 83.13 Mn |
| Dec 31, 2025 | 85.81 Mn |
| Sep 30, 2025 | 74.38 Mn |
| Jun 30, 2025 | 71.54 Mn |
| Mar 31, 2025 | 60.12 Mn |
| Dec 31, 2024 | 60.10 Mn |
| Sep 30, 2024 | 54.27 Mn |
| Jun 30, 2024 | 48.07 Mn |
| Mar 31, 2024 | 40.64 Mn |
| Dec 31, 2023 | 44.39 Mn |
| Sep 30, 2023 | 48.32 Mn |
| Jun 30, 2023 | 38.01 Mn |
| Mar 31, 2023 | 33.20 Mn |
| Dec 31, 2022 | 33.14 Mn |
| Sep 30, 2022 | 29.73 Mn |
| Jun 30, 2022 | 25.31 Mn |
| Mar 31, 2022 | 22.07 Mn |
| Dec 31, 2021 | 21.43 Mn |
| Sep 30, 2021 | 11.06 Mn |